XIDX
PRDA
Market cap122mUSD
Nov 12, Last price
2,470.00IDR
Name
Prodia Widyahusada Tbk PT
Chart & performance
P/E
10.63
P/S
0.96
EPS
232.40
Div yield, %
6.72%
Shrs. gr., 5y
-0.59%
Rev. gr., 5y
4.02%
Revenues
2.28t
+1.31%
Net income
206.79b
-23.47%
CFO
424.13b
-11.02%
Dividend
May 05, 2026162.683 IDR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services. It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.
Key people
Andi Widjaja
President Commissioner · since 2003
Dewi Muliaty
President Director · since 2009
Liana Kuswandi
Finance Director · since 2007
Indriyanti Rafi Sukmawati
Director of Marketing and Business · since 2021
Ida Zuraida
Director of Human Capital and General Affairs · since 2021
Andri Hidayat
Director of Information Technology and Digital Service Transformation · since 2021
Marina Eka Amalia
Corporate Secretary · since 2017
Endang Wahjuningtyas Hoyaranda
Commissioner · since 2015
Gunawan Prawiro Soeharto
Commissioner · since 2003
Keri Lestari
Independent Commissioner · since 2021
Kemal Santoso
Independent Commissioner · since 2021
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||